Skip to main content

Table 3. Genes upregulated>2 fold when comparing pre-treatment to post-treatment using GeoMx immune-oncology markers

From: A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors